Pfizer announced its unaudited financial results for the quarter and half-year ended September 30, 2025. Revenue from operations stood at ₹642.34 crore for the quarter. Net profit after tax was reported at ₹189.02 crore. Basic and diluted earnings per share stood at ₹41.32. The results were approved by the Board of Directors on November 12, 2025.
Financial Performance Overview
Pfizer has released its unaudited financial results for the second quarter (Q2) and the first half of fiscal year 2026, ending on September 30, 2025. The Board of Directors approved these results on November 12, 2025. Here’s a summary of the key financial highlights:
Key Financial Figures – Q2 2026
- Revenue from operations: ₹642.34 crore
- Other income: ₹41.85 crore
- Total income: ₹684.19 crore
- Net profit for the period: ₹189.02 crore
- Basic and diluted EPS: ₹41.32
Year-to-Date (H1 2026) Performance
- Revenue from operations: ₹1,245.39 crore
- Total income: ₹1,354.41 crore
- Net profit for the period: ₹380.77 crore
- Basic and diluted EPS: ₹83.23
Exceptional Items
The financial results include an exceptional item related to the transfer and sale of assets, resulting in a net gain of ₹172.81 crore.
Dividend Announcement
Shareholders approved a final dividend of ₹35 per share (350%) and a special dividend of ₹100 per share (1000%) for Pfizer’s 75th year in India. An additional special dividend of ₹30 per share (300%) was approved related to the gain on asset transfer. Total dividend amounts to ₹165 per share (1650%) for the financial year ending March 31, 2025. This dividend was paid on July 25, 2025.
Segment Information
Pfizer operates primarily in the ‘Pharmaceuticals’ segment.
Source: BSE
